Is Cystatin C a Good Renal Function Test?
Yes, cystatin C is a reliable and valuable test for assessing renal function, particularly when creatinine-based estimates are expected to be inaccurate or when more precise GFR assessment is needed for clinical decision-making.
Guideline-Based Approach to Using Cystatin C
The 2024 KDIGO guidelines provide a clear algorithmic framework for when to use cystatin C 1:
Initial Assessment Strategy
- Start with serum creatinine-based eGFR (eGFRcr) as your initial test for all patients
- Measure cystatin C when eGFRcr is thought to be inaccurate or when more accurate GFR assessment is needed for clinical decisions such as:
- CKD diagnosis or staging
- Drug dosing decisions
- Situations where creatinine-based estimates are unreliable
When Cystatin C Provides Superior Accuracy
The 2024 KDIGO guidelines specifically recommend using eGFRcr-cys (combined creatinine and cystatin C equation) in clinical situations when eGFRcr is less accurate 1. This includes:
Populations with altered creatinine generation:
- Extremes of muscle mass (very low or very high)
- Malnutrition
- Cancer patients
- Heart failure
- Cirrhosis
- Dietary extremes (low-protein, keto, vegetarian, high-protein diets)
- Creatine supplement users
For otherwise healthy individuals with isolated muscle mass changes, eGFRcys alone (without creatinine) may be most appropriate 1.
Key Advantages of Cystatin C
The 2022 NKF-ASN Task Force on race in kidney disease diagnosis emphasized cystatin C's importance, recommending national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults at risk for or with CKD 2. The rationale is compelling:
- Combining filtration markers (creatinine and cystatin C) is more accurate than either marker alone and supports better clinical decisions 2
- Cystatin C does not differ by race like creatinine does 3
- It correlates better with adverse outcomes compared to creatinine 3
- Provides more accurate eGFR when used in combination with creatinine 3
Recent evidence demonstrates that 47% of patients exhibit discordant eGFRcr and eGFRcys results, primarily due to elevated cystatin C with lower creatinine concentrations, which is mitigated by using the combined eGFRcr-cys equation 4. Notably, patients with normal creatinine but elevated cystatin C (>2.06 mg/L) were associated with higher short-term mortality risk 4.
Important Limitations and Caveats
Cystatin C has its own sources of error that you must recognize 1:
- Very low muscle mass (though less affected than creatinine)
- Very high levels of inflammation
- High catabolic states
- Exogenous steroid use
In these situations, if even more accurate assessment is needed, proceed to measured GFR using plasma or urinary clearance of exogenous filtration markers 1.
Special Population Performance
Recent research supports cystatin C's reliability across diverse clinical contexts:
- In neonates with congenital kidney abnormalities: Cystatin C levels correlate with disease severity and clinical outcomes, with cystatin C-based eGFR surpassing creatinine-based estimations 5
- In chronic liver disease: Serum cystatin C is more reliable than creatinine for detecting renal impairment and correlates with disease severity 6
- In adolescents with anorexia nervosa: Cystatin C-based equations consistently outperform creatinine-based formulas, with the CKiD-U25 cystatin C equation showing the strongest correlation with renal scintigraphy 7
Practical Implementation
Do not rely on a single result for clinical decision-making. Use trends in eGFR values (which may require more frequent testing) and other clinical information, including confirmatory testing when needed 2. Report eGFR indexed to standard BSA (mL/min/1.73 m²), but consider non-indexed eGFR values (mL/min) for drug dosing decisions 2.
The evidence strongly supports cystatin C as a good—and often superior—renal function test, particularly when used in combination with creatinine or in populations where creatinine-based estimates are unreliable.